

CURRICULUM VITAE

NAME: Enver Akalin, M.D., FASN, FAST

TITLE: Professor of Medicine and Surgery
Albert Einstein College of Medicine

Medical Director, Kidney Transplantation Program, Montefiore Medical Center

ADDRESS: Montefiore Medical Center
Kidney Transplant Program
111 East 210th street
Bronx, NY 10467

TEL: 718-920-4815

EMAIL: eakalin@montefiore.org

EDUCATION:

1973-1977 Bornova Anadolu Lisesi, Turkey (Junior High School)
1977-1980 Ankara Fen Lisesi, Turkey (Senior High School) (graduated ranking first)
1980-1986 Ege University Medical School, Izmir, Turkey (graduated ranking 4th)

POSTDOCTORAL TRAINING:

7/1987-6/1991 Resident in Internal Medicine, Ege University Medical School,
Izmir, Turkey
7/1991-6/1993 Clinical Fellow in Renal Division, Ege University Medical School,
Izmir, Turkey
7/1993-6/1995 Research Fellow in Renal Division, Brigham and Women's Hospital,
Harvard Medical School, Boston
7/1995-6/1996 Clinical Fellow in Renal Division, Boston University Medical School,
Boston
8/1997-7/1999 Resident in Internal Medicine, Emory University School of Medicine,
Atlanta
8/1999-7/2000 Clinical Transplant Nephrology Fellow in Renal Division, Emory
University School of Medicine, Atlanta

ACADEMIC APPOINTMENTS

8/1996-8/1997 Assistant Professor of Medicine, Renal Division, Baskent
University Medical School, Ankara, Turkey
8/2000- 12/2004 Assistant Professor of Medicine and Surgery, Mount Sinai School of
Medicine, New York
1/2005- 12/2008 Associate Professor of Medicine and Surgery, Mount Sinai School of
Medicine, New York
7/2006-12/2008 Director of Transplant Nephrology Fellowship, Mount Sinai School of
Medicine, New York
2/2009- Professor of Medicine and Surgery, Albert Einstein College of Medicine,
Bronx, NY
7/2012-7/2021 Director of Transplant Nephrology Fellowship Program, Montefiore
Medical Center, Albert Einstein College of Medicine, Bronx, NY

HOSPITAL APPOINTMENTS

8/2000- 12/2008 Medical Director, Pancreas Transplantation, Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York
11/2004-12/2008 Medical Director, Kidney and Pancreas Transplantation, Mount Sinai School of Medicine, New York
2/2009- Medical Director, Kidney and Pancreas Transplantation Program, Montefiore Medical Center, Bronx, NY

CERTIFICATION/LICENSURE

1995 ECFMG Certification (# 0-444-685-2)
1999 American Board of Internal Medicine Certification (#195789)
2000 Licensed New York State (#237443)
2002 American Board of Nephrology Certification (#195789)

HONORS AND AWARDS

1980 Graduated ranking first from Ankara Fen Lisesi
1977-1986 Scholarship from Turkish Scientific and Technical Research Institution
1986 Graduated ranking 4th from Ege University Medical School
1995 Young Investigator Award of the American Society of Transplant Physicians
1996 Young Investigator Award of the American Society of Transplant Physicians
1997 European Dialysis and Transplant Association Travel Award
1998 Associate Professor of Medicine in Nephrology (Turkey)
2002 American Society of Transplant Physicians Faculty Grant
2017 Fellow of American Society of Transplantation
2018 Fellow of American Society of Nephrology
2018 Nominated for American Society of Transplantation Board
2019 Distinguished visiting professorship, Brigham and Women's Hospital, Harvard Medical School

PROFESSIONAL SOCIETIES AND ACTIVITIES

1995- Member of American Society of Nephrology
1995- Member of American Society of Transplantation
1999-2002 Member of American Medical Association
2009- Member of International Society of Nephrology
2010- Member of the Transplantation Society
2003-2008 Member of Medical Board of New York Organ Donor Network
2005-2008 American Society of Transplantation, Clinical Trials Committee Member,
2005-2008 American Society of Nephrology, Transplantation Advisory Group Member
2006-2008 Mount Sinai School of Medicine, Clinical Research Center Advisory Board Member
2008-2009 New York Organ Donor Network, Research and Ethics Subcommittee Member.

2008- 2015	American Society of Nephrology/American Society of Transplantation Renal Accreditation Committee
2013-2014	New York Society of Nephrology, Chairman, Academic Program
2014-2015	New York Society of Nephrology, Secretary/Treasurer
2015-2016	New York Society of Nephrology, Vice President
2016-2017	New York Society of Nephrology, President
2015-2017	Chair, American Society of Transplantation, Transplantation and Immunology, Research Network, Chair, Scientific Review Committee
2016-2018	Chair, Transplant Nephrology Fellowship Accreditation Committee
2016-2018	Board of Directors, American Society of Transplantation Transplant Nephrology Fellowship Training Accreditation Program
2018-2019	Chair, Board of Directors, American Society of Transplantation Transplant Nephrology Fellowship Training Accreditation Program
2018-2019	Fellow of American Society of Transplantation Committee
2019-2020	Chair, Fellow of American Society of Transplantation Committee
2019-	Education Committee Member, The Transplantation Society
2019-	American Society of Transplantation, Medical Directors Task Force Group
2020- 2022	Committee Member, Appointments and Promotions to Professors, Albert Einstein College of Medicine

ORGANIZING ROLES IN SCIENTIFIC MEETINGS

2001-2024	Abstract Review Committee, American Society of Transplantation, Annual Transplant Congress
2002, 2004, 2006, 2008, 2011, 2013, 2015, 2017, 2022, 2023	Abstract Review Committee, American Society of Nephrology, Renal Week
2003	Course Director of “Clinical Update in Kidney/Pancreas Transplantation Course” New York, NY
2003	A national conference to assess antibody mediated rejection in solid organ transplantation. National Institute of Health, Bethesda, Maryland
2006	Chairman, Abstract Review Committee of Clinical Kidney Transplantation, World Transplant Congress 2006
2006	“Clinical Trials Meeting” American Society of Transplantation, Chicago
2007-2011, 2019	Abstract Review Committee, Section Co-chairman, American
2020, 2021	Society of Transplantation
2018	Co-Chair, Clinical Transplantation, Abstract Review Committee, American Society of Nephrology, Renal Week
2021	“COVID-19 in patients with kidney disease and transplantation: What have we learned” Symposium Director
2022	Program Committee Member, The Transplant Society Congress
2022	Co-Chair, Clinical Transplantation, Abstract Review Committee, American Society of Nephrology, Renal Week
2022	“Antibody-mediated rejection” ISN/TTS Educational Webinar
2022	American Society of Transplantation, Medical Directors Forum, ATC 2022, Boston June 2022

EDITORIAL BOARD

2008-2011	Clinical Journal of the American Society of Nephrology
2010-2015	Transplantation
2022-	Frontiers in Transplantation, Chief Editor, section Immunosuppression
2022-	Frontiers in Immunology, Editorial Board, section Alloimmunity and Transplantation
2023-	Associate Editor, Kidney Transplantation

AD HOC REVIEWER

New England Journal of Medicine, Nature Communications, Science Translational Medicine, Journal of Clinical Investigation, Journal of Immunology, American Journal of Transplantation, Transplantation, Journal of the American Society of Nephrology, Clinical Journal of the American Society of Nephrology, American Journal of Kidney Disease, Kidney International, Kidney International Reports, Nephrology Dialysis and Transplantation, Kidney360, Clinical Transplantation, Nature Nephrology, Human Immunology, Transplant International, Pediatric Nephrology, Tissue Antigens, Immunology Methods, Journal of Translational Medicine, Journal of Nephrology, Journal of Clinical Medicine

INVITED SPEAKER

1. “Pregnancy and Kidney Transplantation”. Renal Ground Rounds. University of Chicago. March 2000.
2. “Long-term side effects of immunosuppressive medications after kidney transplantation” Update in Transplantation Course by Emory University. Savannah. April 2000.
3. “Gene array technology to monitor post-transplantation events” Luncheon Symposium. American Society of Transplantation. Chicago. May 2001
4. “Gene expression analysis in human renal allograft biopsy samples using high-density oligonucleotide arrays (Gene Chips)”. Renal Division Grand Rounds, Brigham and Women’s Hospital, Harvard Medical School, Boston. June 2001.
5. “Induction treatment in renal transplant patients”. Pediatric Nephrology Division Conference, Mount Sinai Medical School, New York. December, 2001.
6. “Gene Chip Technology and Kidney Transplantation”. Surgical Ground Rounds. Mount Sinai Medical Center, New York. May, 2002
7. “Update in Kidney Transplantation”. Medicine Ground Rounds. Maimonides Hospital, New York. December, 2002
8. “Mechanisms of chronic allograft nephropathy”. Annual Turkish Nephrology and Hypertension Society Meeting, Antalya, Turkey, May, 2003.
9. “Mechanisms of chronic allograft nephropathy”. Renal Grand Rounds. University of Southern California, Los Angeles. September, 2003.
10. “Transplant genomics” Breakfast symposium. American Transplant Congress, Boston. May 2004.

11. "Intravenous Immunoglobulin treatment in immunologically high-risk kidney transplant recipients". Transplantation Grand Rounds. Tulane Medical School, New Orleans. June 2004.
12. "Mechanisms of chronic allograft nephropathy". Renal Grand Rounds. Yale Medical School. New Haven. October 2004.
13. "Mechanisms of chronic allograft nephropathy". Renal Grand Rounds. Tulane Medical School. New Orleans. August 2004.
14. "Mechanisms of chronic allograft nephropathy". Transplant ground rounds. Northwestern Medical School. Chicago. May 2005.
15. "Mechanisms of chronic allograft nephropathy". European Dialysis and Transplantation Meeting, Istanbul, Turkey. June 2005.
16. "Gene expression profiles of chronic allograft nephropathy" Banff Meeting, Edmonton, Canada. July 2005.
17. "Gene expression profiles of chronic allograft nephropathy" Cornell Medical School, Transplantation Immunology Seminars, New York. August 2005.
18. "Kidney transplantation in sensitized patients: Impact on early allograft function" American Society of Nephrology Annual Meeting, Philadelphia. November 2005.
19. "Transplant immunosuppression: Innovative Protocols". American Society of Nephrology Annual Meeting, Premeeting Symposium, Philadelphia. November 2005.
20. "Antibody mediated rejection: Pathogenesis and diagnosis". World Transplant Congress, Boston. July 2006.
21. "Mechanisms of chronic allograft nephropathy" Turkish Transplantation Congress, Turkey. September 2006.
22. "Update in kidney transplantation 2006" Renal Grand Rounds, Beth Israel Medical Center, New York. September 2006
23. "Mechanisms of chronic allograft nephropathy" Renal grand Rounds, North Shore/LIJ Medical Center, New York. November 2006
24. "Sensitized recipient" Morning workshop. American Transplant Congress, San Francisco. May 2007.
25. "Kidney transplantation in sensitized patients" Renal Grand Rounds, University of Pennsylvania, Philadelphia. December 2007.
26. "Kidney transplantation in sensitized patients" Transplant Grand Rounds, Yale Medical School, March 2008.
27. "Kidney transplantation in sensitized patients" Transplant Grand Rounds, University of Wisconsin School of Medicine, April 2008.
28. "Genomics of chronic allograft dysfunction" International Society of Nephrology Nexus Meeting, Rome, Italy, September 2008.
29. "Options for the sensitized recipient" American Society of Nephrology Annual meeting, Pre-meeting Symposium. Philadelphia, November 2008.
30. "Post-transplant immunosuppression in highly sensitized patients" 2nd International Vicenza Course on Kidney Transplantation, Italy, November 2008.
31. "Debate: Best treatment options for highly sensitized patients". National Kidney Foundation Spring Clinical Meetings. Nashville, TN, March 2009.
32. "Humoral rejection: Clinical and pathological insights". 11th Congress of the Asian Society of Transplantation. Beirut, Lebanon. October 2009.

33. “Utility of genomics in transplantation. 11th Congress of the Asian Society of Transplantation. Beirut, Lebanon. October 2009.
34. “What’s chronic rejection?: Clinical and pathological criteria. 11th Congress of the Asian Society of Transplantation. Beirut, Lebanon. October 2009.
35. “Immune mechanisms of graft destruction in the highly sensitized recipients. 11th Congress of the Asian Society of Transplantation. Beirut, Lebanon. October 2009.
36. “Options for the sensitized recipient”. American Society of Nephrology Annual meeting, Pre-meeting Symposium. San Diego, November 2009.
37. “Impact of rejection on patient management strategies” Annual Scientific Exchange Meeting, American Society of Transplantation. Orlando, December 2009.
38. “Biomarker research” American Society of Transplant Surgeons Winter Symposium. Fort Lauderdale, January 2010.
39. “Pretransplant immunologic risk assessment for management of immunosuppressive treatment” Renal Grand Rounds, Jacobi Medical Center. Bronx, NY, February 2010.
40. “Update in kidney transplantation” Albert Einstein Medical College Medicine Grand Rounds. Bronx, NY, May 2010
41. “Pretransplant immunologic risk assessment” North Shore-Long island Jewish Hospital Renal Grand Rounds. Long Island, NY, April 2010.
42. “Update in kidney transplantation” Bronx Lebanon Medicine Grand Rounds. Bronx, NY, May 2010
43. “Pretransplant immunologic risk assessment” Montefiore/Einstein Abdominal Organ Transplant Symposium “Innovations in Transplantation” Bronx, NY, June 2010.
44. “Pretransplant immunologic risk assessment” Annual Turkish Society of Nephrology Meeting, Antalya, Turkey, September 2010
45. “Mechanisms of chronic allograft injury” Annual Turkish Society of Nephrology Meeting, Antalya, Turkey, September 2010
46. “Options for the sensitized recipient” American Society of Nephrology Annual meeting, Pre-meeting Symposium. Denver, November 2010.
47. “Who should receive combined liver and kidney transplantation” American Society of Nephrology Annual meeting. Denver, November 2010.
48. “Combined Liver and Kidney Transplantation” Transplant Grand Rounds, Yale School of Medicine, New Haven. December 2010.
49. “Kidney transplantation in patients with rheumatologic disease” Rheumatology grand rounds, Albert Einstein College of Medicine, NY. December 2010.
50. “Pretransplant immunologic risk assessment”. Renal Grand Rounds, Brown University, Rhode Island, March 2011.
51. “Chronic allograft injury: Mechanisms and treatment”. Turkish Transplantation Congress 2011, Antalya, Turkey, October 2011.
52. “Options for the sensitized recipient” American Society of Nephrology Annual meeting, Pre-meeting Symposium. Philadelphia, November 2011.
53. “Application of microarrays in sensitized kidney transplant recipients”. University of Pittsburg Transplant Grand Rounds. Pittsburg, April 2012.
54. “Transplantation of sensitized patients”. National Kidney Foundation Spring Clinical meetings, Transplant Course. Washington, May 2012.
55. “Desensitization”. National Kidney Foundation Spring Clinical meetings. Washington, May 2012.

56. "Options for the sensitized recipient" American Society of Nephrology Annual meeting, Pre-meeting Symposium. San Diego, November 2012
57. "Kidney transplantation in sensitized kidney transplant recipients: Application of microarrays to unanswered questions". Transplant Grand Rounds, Emory University Medical School, Atlanta, December 2012.
58. "Options for the sensitized recipient" American Society of Nephrology Annual meeting, Pre-meeting Symposium. Atlanta, November 2013
59. "Molecular approach to sensitized kidney transplant recipients" Renal Grand Rounds, University of California at San Francisco, February 2014.
60. "Update in Kidney Transplantation 2014" Renal Grand Rounds, Jacobi Medical Center, Bronx, NY, May 2014.
61. "Clinical and molecular approach to chronic allograft injury". Annual Turkish Nephrology, Hypertension and Transplantation Meeting, Turkey, April, 2015.
62. "Desensitization methods in immunologically high-risk patients". Annual Turkish Nephrology, Hypertension and Transplantation Meeting, Turkey, April, 2015.
63. "The role of the molecular microscope: The molecular approach to the sensitized recipient. American Transplant Congress, Philadelphia, May 2015.
64. "Why do allografts fail? : Molecular approach to chronic allograft injury". University of Pennsylvania Transplant Grand Rounds, Philadelphia, May 2015.
65. "Clinical and molecular significance of microvascular inflammation". Banff Allograft Pathology Meeting, Vancouver, October 2015.
66. Chronic T cell-mediated rejection: Does it exist and how to diagnose by molecular microscope? American Transplant Congress, Boston, June 2016
67. "Kidney Transplantation in HCV+ patients. Inspire Telementoring case conferences. Bronx, NY October 2016.
68. "Molecular approach to chronic allograft injury" Mount Sinai School of Medicine Nephrology Grand Rounds, New York, January 2017.
69. "Molecular correlates of chronic T-cell mediated rejection". Banff Allograft Pathology Meeting, Barcelona, Spain, March 2017
70. "Transplantation and Genomics". Annual Turkish Nephrology, Hypertension and Transplantation Meeting, Turkey, April, 2017.
71. "Pretransplant immunologic risk assessment". Annual Turkish Nephrology, Hypertension and Transplantation Meeting, Turkey, April, 2017.
72. "A Molecular approach to chronic allograft injury" New York University School of Medicine Nephrology Grand Rounds, New York, October 2017.
73. "Renal Replacement Therapy" Lincoln Hospital Medicine Grand Rounds, Bronx, New York, October 2017.
74. "Kidney Transplantation: Past, present and future". St. Johns Episcopal Hospital, Medicine Grand Rounds, Far Rockaway, NY, October 2017.
75. "A molecular approach to chronic allograft injury". Virginia Commonwealth University, Nephrology Grand Rounds. May 2018.
76. "Pretransplant immunologic risk assessment in sensitized patients". Virginia Commonwealth University, Transplant Grand Rounds. May 2018.
77. "Therapeutic approaches to acute rejection" American Transplant Congress. May 2018.
78. "Molecular diagnostics in kidney transplantation" Annual Turkish Society of Nephrology meeting, Antalya, Turkey, October 2018.

79. “A molecular and clinical approach to chronic allograft injury”. Annual Turkish Society of Nephrology meeting, Antalya, Turkey, October 2018.
80. “A molecular approach to chronic allograft injury: Benefits and limitations. University of Wisconsin at Madison. Nephrology Grand Rounds, March 2019.
81. “Molecular diagnostics and biomarkers in kidney transplantation”. University of Wisconsin at Madison. Transplant Surgery Grand Rounds, March 2019.
82. “Monitoring donor specific anti-HLA antibodies before and after kidney transplantation” Cordoba Society of Nephrology Meeting, Cordoba, Argentina, April 2019.
83. “Application of molecular microscope to kidney transplantation: Molecular diagnosis of antibody-mediated rejection”. Cordoba Society of Nephrology Meeting, Cordoba, Argentina, April 2019.
84. “Pretransplant immunologic assessment of kidney transplant recipients for immunosuppressive treatment selection” Annual Turkish Nephrology, Hypertension and Transplantation Meeting, Turkey, April, 2019
85. “Kidney transplantation in patients with systemic lupus and vasculitis” Jacobi Rheumatology Grand Rounds, Bronx, May 2019
86. “Molecular Approaches to Chronic Allograft Injury”. American Transplant Congress, pre-meeting symposium. Boston, June 2019.
87. “Molecular Assessment of Pre-implantation Biopsies”. American Transplant Congress, mid-day symposium. Boston, June 2019.
88. “Current State of Desensitization Protocols”. American Transplant Congress, Lunch symposium. Boston, June 2019.
89. “Molecular approaches to chronic allograft injury”. Brigham and Women’s Hospital, Nephrology Grand Rounds, June 2019
90. “Potential Role for Morphometry, Molecular Diagnosis in Further Refining the Definition of Chronic TCMR”, ASHI/Banff joint scientific meeting, Pittsburgh, September 2019
91. “COVID-19 and kidney transplantation: Montefiore Medical Center experience”. Fighting the pandemic together, COVID-19, Transcontinental Transplant Forum, April, 2020
92. “COVID-19 and kidney transplantation”. Brigham and Women’s Hospital, Nephrology Grand Rounds, June 2020
93. “Kidney transplantation and dialysis during COVID pandemics” ECHO lecture series, August 2020
94. “COVID-19 and kidney transplantation” Montefiore Medical Center experience”. ISN-TTS Webinar: Global impact of COVID-19 in kidney transplantation, June 2020.
95. “COVID-19 and kidney transplantation”. ULM Medical School, Nephrology Grand Rounds, Ulm, Germany. October 2020.
96. “Clinical, histological and molecular assessment of deceased donors” nephrology Grand Rounds, Albert Einstein College of Medicine, Bronx. January 2021
97. “COVID-19 and kidney transplantation”. CAPA Nephrology and Transplant Annual meeting, Istanbul, Turkey. February 2021.
98. “COVID-19 and kidney transplantation”. Rhode Island Hospital Nephrology Grand Rounds, April 2021
99. “Immune response to SARS-CoV2” COVID-19 in kidney disease and transplantation: What have we learned? International symposium, May 2021
100. “Antibody response to mRNA vaccination in kidney transplant recipients” American Transplant Congress, June 2021

101. “Preop and postop implementation in kidney transplant recipients to improve graft survival” Online Symposium of Kidney Transplantation Academy. August 2021
102. What Is in Current Use, Assays as Standalone or Part of a Diagnostic Panel? AST Virtual Consensus Conference. The Evolving Use of Biomarkers to Personalize Care in Renal and Cardiac Transplantation. January 2022
103. “Anti-HLA antibodies and pretransplantation immunologic risk assessment” Turkish Society of Nephrology, Kidney Transplantation lecture series, May 2022
104. “Transplant nephrology fellowship: History, current status and future directions” American Society of Transplantation, Medical Directors Forum, June 2022, Boston
105. “How to increase kidney transplantation? : Montefiore Medical Center experience. American Society of Transplantation, Medical Directors Forum, June 2022, Boston
106. “Chronic T cell mediated rejection” 10th International Conference: Living donor abdominal transplantation state of the art 2022, Gubbio, Italy, June 2022
107. “Clinical updates in molecular diagnostics for kidney transplantation” 10th International Conference: Living donor abdominal transplantation state of the art 2022, Gubbio, Italy, June 2022
108. “Molecular diagnostics and biomarkers for diagnosis of rejection in kidney transplantation”. Kidney transplantation novel applications congress, October 2022, Gaziantep, Turkey
109. “Molecular microscope for diagnosis of kidney transplant rejection” Turkish Society of Nephrology meeting, November 2022, Antalya Turkey
110. “Molecular diagnostics for allograft injury” University of Maryland, Transplantation Grand Rounds, April 2023.
111. “Molecular diagnostics for allograft injury” Columbia Medical School, Nephrology Grand Rounds, October 2023.
112. “Intra-graft gene transcript detection” American Society of Nephrology, Renal Week, Philadelphia, November 2023
113. “Comparison of different blood transcriptomic assays for diagnosis of rejection and immune quiescence” American Transplant Congress, Philadelphia, May 2024

CHAIRPERSON

1. American Society of Transplantation Congress, Chicago 2001. “Antibodies and Immunomodulation”
2. American Society of Nephrology/International Society of Nephrology, World Congress of Nephrology, San Francisco 2001. “Immunology and Chemokines”
3. Official Symposium of the American Society of Nephrology/International Society of Nephrology, World Congress of Nephrology, San Francisco 2001. “Application of Molecular Techniques in Transplantation”
4. American Transplant Congress, Washington 2002. “Molecules and Mechanisms in AR/CR”
5. American Transplant Congress, Washington 2003. “Acute Rejection and Immunologic Monitoring”
6. American Transplant Congress, Boston 2004. “Alloantibodies and positive cross-match in kidney transplantation”
7. American Society of Nephrology, San Louis 2004. “Allograft dysfunction”
8. World Transplant Congress, Boston 2006. “Protocol biopsies and chronic rejection”

9. American Transplant Congress, San Francisco 2007. “Transplant glomerulopathy”
10. American Society of Nephrology, Philadelphia 2008. “Antibody-mediated rejection”
11. American Transplant Congress, Boston 2009. “Acute rejection”
12. American Society of Nephrology Annual Meeting, San Diego 2009. “B cells in Transplantation. From bench to clinics”.
13. American Transplant Congress, San Diego 2010. “Acute rejection”
14. American Transplant Congress, Philadelphia 2011. “Acute rejection”
15. American Transplant Congress, Boston 2012. “Antibody-mediated rejection”
16. American Society of Nephrology, Renal Week San Diego 2015.
17. American Transplant Congress, Boston 2019
18. American Transplant Congress, Boston 2021
19. American Society of Nephrology, Renal Week, Philadelphia 2023

CLINICAL STUDIES

PRINCIPAL INVESTIGATOR INITIATED STUDIES AND GRANTS (ACTIVE)

1. Prospective evaluation of donor and recipient *APOLI* genotypes on outcomes in kidney transplantation (APOLLO RFA/UO1, DK116040 grant)
Period: 06/01/2018 – 6/30/2024 Sponsor: NIH/ NIDDK
Site PI: Enver Akalin (site budget \$149,695)
2. R01DK122682-01. Dissecting the role of dynamic epigenome prompting pathways leading to kidney allograft fibrosis.
Period: 7/1/2019-6/30/2024. Sponsor NIH/NIDDK
Site PI: Enver Akalin (site budget: \$353,180)
3. R01DK109581-01 Assessment of donor quality for improving post-kidney transplant outcomes. Period: 04/14/2016-12/30/2021. Sponsor: NIH/ NIDDK 4 center application.
Site PI: Enver Akalin (Site Budget \$368,350)
4. R01DK109581-01 Assessment of donor quality for improving post-kidney transplant outcomes (Renewal). Period: 04/01/2024-03/31/2029. Sponsor: NIH/ NIDDK.
Site PI: Enver Akalin (Site Budget \$285,000)
5. Blood and tissue gene expression profiles of allograft injury in kidney transplant recipients
Sponsored by CareDx
PI: Enver Akalin (Budget \$290,000)
6. Assessing benchmarks for Allosure and Allomap testing in simultaneous kidney and pancreas transplant recipients
Sponsored by CareDx
PI: Enver Akalin, Investigator initiated research
(Budget \$136,625)
7. The Kidney Solid Organ Response Test (kSORT) blood gene expression assay for non-invasive detection of rejection in kidney transplant recipients
PI: Enver Akalin, Investigator initiated research
Budget \$118,563

PRINCIPAL INVESTIGATOR INITIATED STUDIES AND GRANTS (PAST)

1. Mechanisms of chronic allograft nephropathy. AST Council's Grant. Sponsored by American Society of Transplantation
2. Thymoglobulin and Intravenous Immunglobulin induction treatment in CDC B and Flow T/B crossmatch positive kidney transplant recipients. Sponsored by Sangstat
3. Rapid steroid withdrawal in African American kidney transplantation recipients. Sponsored by Fujisawa.
4. Rapamycin treatment in chronic allograft nephropathy. Sponsored by Wyeth.
5. Noninvasive monitoring to predict outcome in de novo kidney transplant recipients. CTOT-1 study. Sponsored by NIH.
6. Mechanisms and treatment of chronic allograft injury (CAI) due to calcineurin inhibitor (CNI) toxicity. Sponsored by Novartis.
7. Immune monitoring of kidney transplant recipients. Sponsored by Einstein/Montefiore Abdominal Transplant Center.
8. R01 DK093770 Novel Biomarkers to Predict Outcomes in Kidney Transplant Recipients. (Principal investigator Chirag Parikh, Yale School of Medicine. Sponsored by NIH. Site PI: Enver Akalin (subcontract with Yale School of Medicine) (Site Budget \$31,500)
9. UO1 AIO63594. COVID-19 infection and disease in kidney transplant recipients. Period: 6/1/2019-8/30/2021. Sponsor NIH/NIDDK. Site PI: Enver Akalin (site budget: \$84,955)

PRINCIPAL INVESTIGATOR IN MULTICENTER TRIALS (CURRENT)

1. TruGraf® Long-term Clinical Outcomes Study (TRULO). Sponsored by Transplant Genomics Inc.
2. International registry study for recurrent glomerular disease after kidney transplantation. Sponsored by TANGO Registry.
3. A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination with Belatacept and MPA Compared to Standard of Care Immunosuppression in *de novo* Renal Transplant Recipients (ASCEND).

PRINCIPAL INVESTIGATOR IN MULTICENTER TRIALS (PAST)

1. A 6 month, multicenter, randomized, open-label study to compare the impact of Neoral C2 monitoring on safety and efficacy outcomes in de novo kidney transplant recipients. Protocol # COLO 400A US05, sponsored by Novartis
2. One year, multi-center, open-label, prospective, randomized study to compare the effect of two Neoral C-2h maintenance targets, beyond two months post-transplant on renal function, in the context of an immunosuppressive regimen consisting of Myfortic, Simulect and Steroids. Protocol # CERL080A2405-US01, sponsored by Novartis
3. Randomized, prospective, phase II study comparing Thymoglobulin in a rapid discontinuation of corticosteroids protocol with standard corticosteroid therapy in living donor renal transplantation using mycophenolate mofetil and tacrolimus maintenance therapy. Protocol# SMC-101-1025, sponsored by Sangstat.

4. A randomized open-label study to compare the safety and efficacy of two different sirolimus regimens with a tacrolimus+mycophenolate regimen in de novo renal allograft recipients. Sponsored by Wyeth.
5. An open label; prospective, randomized, controlled, multi-center study assessing fixed dose vs. concentration controlled Cellcept regimens for patients following a single organ renal transplantation in combination with full dose and reduced dose calcineurin inhibitors. Sponsored by Roche.
6. A Randomized, Open Label Comparative Evaluation of the Safety and Efficacy of Sirolimus versus Cyclosporine when Combined in a Regimen containing Basiliximab, Mycophenolate Mofetil, and Corticosteroids in Primary De Novo Renal Allograft Recipients. Sponsored by Wyeth.
7. 12-month open label, randomized, multicenter sequential cohort, dose-finding study to evaluate the efficacy, safety and tolerability of oral AEB071 vs tacrolimus in combination with myfortic, simulect, and corticosteroids in de novo renal transplant recipients. Sponsored by Novartis.
8. A two part, A Phase ½. Safety, PK and PD study of TOL101, an anti-TCR monoclonal antibody for prophylaxis of organ rejection in patients receiving kidney transplantation. Sponsored by Tolera.
9. A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Safety and Efficacy of Single Intravenous Doses of ASP8597 (Diannexin) in Kidney Transplant Recipients. Sponsored by Astellas.
10. Treatment of BKV in kidney transplant recipients. Multicenter Trial.
11. A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de novo Kidney Transplant Recipients ASKP1240". Sponsored by Astellas.
12. An historical-cohort multi-center, observational study to identify and characterize calcineurin inhibitor usage patterns post-transplant and impact on allograft outcome. Sponsored by BMS.
13. A Randomized, Parallel-Group, Double blind, Placebo-Controlled, Multi-Center Study Of Eculizumab For The Prevention Of Delayed Graft Function After Kidney Transplantation In Adult Subjects At Increased Risk Of Delayed Graft Function. Sponsored by Alexion.
14. A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant efficacy and safety Outcomes with an eveRolimus-based regiMe (TRANSFORM), sponsored by Novartis.
15. Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation. Sponsored by Alexion.
16. Astagraf XL to understand the impact of immunosuppression on de novo DSA development and chronic immune activation in kidney transplantation. Sponsored by Astellas.
17. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor. Sponsored by Astellas.
18. A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de novo Kidney Transplant Recipients (ASKP1240). Sponsored by Astellas.

19. A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney. Sponsored by Angion.
20. Evaluation of patient outcomes from the kidney allograft outcomes allosure registry (KOAR). Sponsored by CareDx
21. Outcomes of KidneyCare in Renal Allografts: Allosure and Allomap registry (OKRA study). Sponsored by CareDx
22. A pivotal phase 3 trial to evaluate the safety and efficacy of clazakizumab for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients. Sponsored by Vitaeris.
23. A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients. Sponsored by Amplyx.

CHAPTERS

1. Schroppel B, **Akalin E.** Transplant immunology and immunosuppression. Therapy in Nephrology and Hypertension. A companion to Brenner and Rector's the Kidney. Saunders, Elsevier. Third Edition 2008.

REVIEW ARTICLES

1. **Akalin E.**, Chandraker A, Sayegh MH, Turka LA. Role of the CD28-B7 costimulatory interaction in alloimmune responses. *Kid Int* 1996; 51, suppl.58 : S8-10. PMID: 9067935
2. **Akalin E.**, Murphy B. Gene Polymorphism and transplantation. *Cur Op Immunol* 2001 ; 13 : 572-576. doi: 10.1016/s0952-7915(00)00261-2.PMID: 11544006
3. **Akalin E.**, Bromberg JS. Gene therapy and solid organ transplantation. *Kid Int* 2002; 61, Suppl 1: 56-60. doi: 10.1046/j.1523-1755.2002.0610s1056.x.PMID: 11841614
4. Schroppel B, **Akalin E.** T cell profiling and gene expression in tolerance. *Cur Op Organ Transplant* 2004; 9:264-268
5. **Akalin E.**, Bromberg JS. Intravenous immunoglobulin induction treatment in flowcytometry cross-match positive kidney transplant recipients. *Human Immunology* 2005; 66: 359-363. doi: 10.1016/j.humimm.2005.01.027.PMID: 15866698
6. **Akalin E.**, Pascual M. Sensitization after kidney transplantation. *Clin J Am Soc of Nephrol* 2006; 1:3:433-440. doi: 10.2215/CJN.01751105. PMID: 17699242
7. **Akalin E.**, Watschinger B. Antibody-mediated rejection. *Semin Nephrol* 2007; 27 (4): 393-407. doi: 10.1016/j.semnephrol.2007.05.001.PMID: 17616272
8. Dinavahi R, **Akalin E.** Preemptive kidney transplantation in patients with diabetes mellitus. *Endocrinology and Metabolism Clinics of North America* 2007; 36(4): 1039-1049. doi: 10.1016/j.ecl.2007.07.005.PMID: 17983935
9. **Akalin E.** Immunosuppression minimization protocols: how should they be monitored? *Nature Clin Practice Nephrol* 2008; 4:484-485. doi: 10.1038/ncpneph0910.PMID: 18679390
10. **Akalin E.** Posttransplant immunosuppression in highly sensitized patients. *Cont Nephrol* 2008; 4(9):484-485. doi: 10.1159/000170810.PMID: 19001811
11. Papafragkakakis H, Martin P, **Akalin E.** Combined liver and kidney transplantation. *Curr Opin Organ Transplant.* 2010;15(3):263-8. doi: 10.1097/MOT.0b013e328338f638.PMID: 20386445

12. **Akalin E** and O'Connell PJ. Genomics of chronic allograft injury. *Kidney Int* 2010; 78:suppl 119: S33-37. doi: 10.1038/ki.2010.420.PMID: 21116315
13. Marfo K, Lu A, Ling M, **Akalin E**. Desensitization protocols and their outcomes. *Clin J Am Soc Nephrol* 2011; 6 : 922-936. doi: 10.2215/CJN.08140910.PMID: 21441131
14. **Akalin E**. A new treatment option for highly sensitized patients awaiting kidney transplantation. *American Journal of Kidney Disease* 2018; 71 (4) : 458-460. doi: 10.1053/j.ajkd.2017.10.024. PMID: 29352605
15. von Moos S, **Akalin E**, Mas V, Mueller TF. Assessment of Organ Quality in Kidney Transplantation by Molecular Analysis and Why It May Not Have Been Achieved Yet. *Front Immunol.* 2020 May 12;11:833. doi: 10.3389/fimmu.2020.00833. PMID: 32477343
16. Cravedi P, Schold JD, Safa K, Kates OS, Elfadawy N, Mannon RB, Shah MB, Hammond SP, Avery R, Guerrero Miranda C, Riella LV, Jowsey-Gregoire S, **Akalin E**, Camirand G, Alegre ML, Azzi J. The COVID-19 pandemic: A community approach. *Clin Transplant* 2020 Nov;34(11): e14059. doi: 10.1111/ctr.14059. Epub 2020 Sep 28. PMID: 32762055
17. Azzi Y, Bartash R, Scalea J, Loarte-Campos P, **Akalin E**. COVID-19 and Solid Organ Transplantation: A Review Article. *Transplantation.* 2021 Jan 1;105(1):37-55. doi: 10.1097/TP.0000000000003523. PMID: 33148977
18. Ajaimy M, Liriano-Ward L, Graham J, and **Enver Akalin**. Risks and benefits of kidney transplantation during the covid pandemic: transplant or not transplant? *Kidney360 July 2021, 2 (7) 1179-1187.* doi: 10.34067/KID.0002532021. PMID: 35368354
19. COVID-19 and kidney transplantation. Luz-Liriano-Ward, Yorg Azzi, Enver Akalin. NEPHSAP May 2022.
20. Impact of Deceased-Donor Acute Kidney Injury on Kidney Transplantation. Yaffe HC, von Ahrens D, Urioste A, Mas VR, **Akalin E**. Transplantation. 2023 Nov 22. doi: 10.1097/TP.0000000000004848. Online ahead of print. PMID: 37990359
21. Inside look: Are noninvasive biomarkers up to standard? **Akalin E**, Mas VR. Am J Transplant. 2023 Nov 3:S1600-6135(23)00831-6. doi: 10.1016/j.ajt.2023.10.029. Online ahead of print. PMID: 37925160

ORIGINAL ARTICLES

1. **Akalin E**, Hancock WW, Perico N, Remuzzi B, Imberti O, Carpenter CB, Sayegh MH. Blocking cell microtubule assembly inhibits alloimmune response in vitro and prolongs renal allograft survival by selective inhibition of Th1 and sparing Th2 cell function in vivo. *J Am Soc Nephrol* 1995; 5: 1418-1425. doi: 10.1681/ASN.V571418.PMID: 7703379
2. Sayegh MH, **Akalin E**, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. *J Exp Med* 1995; 181: 1869-1874. doi: 10.1084/jem.181.5.1869.PMID: 7536798
3. Khoury SJ, **Akalin E**, Chandraker A, Turka LA, Linsley PS, Sayegh MH, Hancock WW. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. *J Immunol* 1995; 155: 4521-4524. PMID: 7594447
4. Gallon L, Watschinger B, Murphy B, **Akalin E**, Sayegh MH, Carpenter CB. The indirect pathway of allorecognition: The occurrence of self-restricted T cell recognition of allo-MHC peptides early in acute renal allograft rejection and its inhibition by conventional immunosuppression. *Transplantation* 1995; 59, 4: 612-616. PMID: 7878766

5. Shin YT, Adams DH, Wyner LR, **Akalin E**, Sayegh MH, Karnovsky MJ. Intrathymic tolerance in the Lewis to F344 chronic cardiac allograft rejection model. *Transplantation* 1995; 12: 1647–1653. doi: 10.1097/00007890-199506270-00001.PMID: 7604433
6. Hancock WW, Grey ST, Hau L, **Akalin E**, Orthner C, Sayegh MH, Salem HH. Binding of Activated Protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signalling and monocyte-dependent proliferative response. *Transplantation* 1995; 60: 1525-1532. doi: 10.1097/00007890-199560120-00026.PMID: 8545885
7. Murphy B, **Akalin E**, Watschinger B, Carpenter CB, Sayegh MH. Inhibition of the alloimmune response with synthetic nonpolymorphic class II MHC peptides. *Transplant Proc* 1995; 27,1: 409-410. PMID: 7879041
8. Shin YT, Adams DH, Wyner LR, **Akalin E**, Sayegh MH, Karnovsky MJ. Intrathymic injection of donor splenocytes plus systemic anti-lymphocyte serum or anti-lymphocyte serum alone prolongs cardiac allograft survival and inhibits graft arteriosclerosis in the Lewis to F344 chronic allograft rejection model. *Transplant Proc* 1995; 27,3: 2112-2114. PMID: 7792902
9. **Akalin E**, Chandraker A, Russell ME, Turka LA, Sayegh MH, Hancock WW. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: Inhibition of T cell mediated and humoral immune responses in vivo. *Transplantation* 1996; 62: 1942-1945. doi: 10.1097/00007890-199612270-00047.PMID: 8990393
10. Russell ME, Hancock WW, **Akalin E**, Wallace AF, Glysing-Jensen T, Willett T, Sayegh MH. Chronic cardiac rejection in the Lewis to F344 rat model: Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. *J Clin Invest* 1996; 97: 833-838. doi: 10.1172/JCI118483.PMID: 8609241
11. Perico N, Ostermann D, Bontempelli M, Morigi M, Amuchastegui CS, Zoja C, **Akalin E**, Sayegh MH, Remuzzi G. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. *J Am Soc Nephrol* 1996; 7 :594-601. doi: 10.1681/ASN.V74594. PMID: 8724893
12. Onodera K, Lehmann M, **Akalin E**, Volk HD, Sayegh MH, Kupiec-Weglinski JW. Induction of infectious tolerance to MHC-incompatible cardiac allografts in CD4 MAB-treated sensitized rat recipients. *J Immunol* 1996; 157: 1944-1950. PMID: 8757313
13. **Akalin E**, Hendrix RC, Polavarapu RG, Pearson TC, Neylan JF, Larsen CP, Lakkis FG. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. *Transplantation* 2001; 72: 948-953. doi: 10.1097/00007890-200109150-00034.PMID: 11571464
14. **Akalin E**, Neylan JF. The influence of Duffy blood group on renal allograft outcome in African-Americans. *Transplantation* 2003; 7: 1496-1500. doi: 10.1097/01.TP.0000061228.38243.26.PMID: 12792503
15. **Akalin E**, Dikman S, Murphy B, Bromberg JS, Hancock WW. Glomerular infiltration by CXCR3+ and ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. *Am J Transplant* 2003; 3:1116-1120. doi: 10.1034/j.1600-6143.2003.00151.x.PMID: 12919091
16. **Akalin E**, Sehgal V, Ames S, Hossain S, Daly L, Murphy B, Bromberg JS. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. *Am J Transplant* 2003; 3:731-735. doi: 10.1034/j.1600-6143.2003.00140.x.PMID: 12780565

17. **Akalin E**, Ames S, Sehgal V, Fotino M, Daly L, Murphy B, Bromberg JS. Intravenous immunoglobulin (IVIG) and Thymoglobulin facilitate kidney transplantation in complement dependent cytotoxicity (CDC) B cell and flow cytometry (FC) T and/or B cell cross-match positive patients. *Transplantation* 2003; 76:1444-1447. doi: 10.1097/01.tp.0000146845.93929.ec.PMID: 15785390
18. Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, Florman S, Gondolesi GE, Krieger N, Ames S, Bromberg JS, **Akalin E**. Post liver transplant acute renal failure: Factors predicting development of end stage renal disease. *Clinical Transplantation* 2004; 18: 94-99. doi: 10.1046/j.1399-0012.2003.00132.x.PMID: 15108777
19. **Akalin E**, Murphy B, Sehgal V, Ames S, Daly L, Bromberg JS. Rapid steroid withdrawal in hepatitis C virus positive kidney transplant recipients. *Clinical Transplantation* 2004; 18: 384-389. doi: 10.1111/j.1399-0012.2004.00177.x.PMID: 15233814
20. **Akalin E**, Ames S, Sehgal V, Murphy B, Bromberg JS. Safety of using hepatitis B core antibody or surface antigen positive donors in kidney or pancreas transplantation. *Clinical Transplantation* 2005; 19: 364-366. doi: 10.1111/j.1399-0012.2005.00350.x.PMID: 15877799
21. Vincenti F, Mendez R, Curtis J, Light J, Pearson T, Wu YM, Katz SM, **Akalin E**, Esterl R, Gugliuzza K, Shihab F, Jordan S, Jonsson J, Molmenti E, Barbeito R. A multicenter, prospective study of C2-monitored Neoral in a U.S. population of de novo renal transplant recipients. *Transplantation* 2005; 80: 910-916. doi: 10.1097/01.tp.0000173802.70980.50.PMID: 16249738
22. Gallon L, **Akalin E**, Lynch P, Rothberg L, Parker MA, Schiano T, Abecassis M, and Murphy B. Angiotensin converting enzyme (ACE) gene D/D polymorphism as a determinant for the development of chronic nephrotoxicity from Calcineurin inhibitors in liver transplant recipients. *Transplantation* 2005; 81: 463-468. doi: 10.1097/01.tp.0000185305.63759.d3.PMID: 16477235
23. Hotchkiss H, Chu T, Hancock WW, Schroppel B, Kretzler M, Schmid H, Liu Y, Dikman S, **Akalin E**. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. *Transplantation* 2006; 81: 342-349. doi: 10.1097/01.tp.0000195773.24217.95.PMID: 16477218
24. Gondolesi G, Blondeau B, Maurette R, Hoppenhauer L, Rodriguez-Laiz G, Schiano T, Boros P, Bromberg J, **Akalin E**, and Sauter B. Pretransplant immunomodulation of highly sensitized small bowel transplant candidates with intravenous immune globulin. *Transplantation* 2006; 81: 1743-1746. doi: 10.1097/01.tp.0000226078.94635.76.PMID: 16794543
25. Diane Cibrik, Herwig-Ulf Meier-Kriesche, Barbara Bresnahan, You Min Wu, Goran Klintmalm, Clifton E Kew, Paul C Kuo, John Whelchel, David Cohen, Prabakar Baliga, **Enver Akalin**, Enrico Benedetti, Francis Wright, Bonnie Lieberman, Bettina Ulbricht, Stephen Jensik on behalf of the *myfortic*-US01 Renal Transplant Study Group. Renal function with cyclosporine C₂ monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. *Clin Transplant* 2007; 21(2):192-201. doi: 10.1111/j.1399-0012.2006.00622.x.PMID: 17425744
26. Ommen ES, Schroppel B, Kim JY, Gaspard G, **Akalin E**, de Boccardo G, Sehgal V, Lipkowitz M, Murphy B. Routine use of ambulatory blood pressure monitoring in

- potential living kidney donors. *Clin J Am Soc Nephrol* 2007; 2: 1030-1036. doi: 10.2215/CJN.01240307.PMID: 17702722
27. **Akalin E**, Dinavahi R, Dikman S, de Boccardo G, Friedlander R, Schroppel B, Sehgal V, Bromberg JS, Murphy B. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. *Clin J Am Soc Nephrol* 2007; 2(6): 1261-1267. doi: 10.2215/CJN.02420607.PMID: 17942771
 28. **Akalin E**, Dinavahi R, Friedlander R, de Boccardo G, Sehgal V, Schroppel B, Bhaskaran M, Lerner S, Fotino M, Murphy B, Bromberg JS. The addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. *Clin J Am Soc Nephrol* 2008; 3(4): 1160-1167. doi: 10.2215/CJN.05321107. PMID: 18337549
 29. de Boccardo G, Kim JY, Schiano Td, Maurette R, Gagliardi R, Murphy B, Emre S, and **Akalin E**. The burden of chronic kidney disease in long-term liver transplant recipients. *Transplant Proc* 2008; 40 (5): 1498-1503. doi: 10.1016/j.transproceed.2008.03.099.PMID: 18589138
 30. **Akalin E**, Ganeshan SV, Winston J, Muntner P. Hyperuricemia is associated with development of the composite outcomes of new cardiovascular disease and chronic allograft nephropathy. *Transplantation* 2008; 86: 652-658. doi: 10.1097/TP.0b013e3181814f5b.PMID: 18791445
 31. Rafiq M, de Boccardo G, Schroppel B, Bromberg J, Sehgal V, Dinavahi R, Murphy B, **Akalin E**. Differential outcomes in 3 types of acute-antibody mediated rejection. *Clinical Transplantation* 2009; 23(6): 951-957. doi: 10.1111/j.1399-0012.2009.01036.x. PMID: 19624692
 32. Sawinski S, Wyatt CM, Casagrande L, Myoung P, Bijan I, **Akalin E**, Schroppel B, de Boccardo G, Sehgal V, Dinavahi R, Lerner S, Ames S, Bromberg J, Huprikar S, Keller M, Murphy B. Factors associated with failure to list HIV-positive kidney transplant candidates. *Am J Transpl* 2009; 9: 1467-1471. doi: 10.1111/j.1600-6143.2009.02637.x. PMID: 19459817
 33. Kim JY, **Akalin E**, Dikman S, Gagliardi R, Schiano T, Bromberg J, Murphy B, de Boccardo G. The variable pathology of kidney disease after liver transplantation. *Transplantation* 2010; 89(2): 215-221. doi: 10.1097/TP.0b013e3181c353e5.PMID: 20098285
 34. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC; TRIMS Study Investigators. A prospective randomized study evaluating early corticosteroid withdrawal with Thymoglobulin in living kidney transplantation. *Clin Transplant*. 2010 Jan-Feb;24(1):73-83. doi: 10.1111/j.1399-0012.2009.01127.x.PMID: 19930408
 35. Dinavahi R, George A, Tretin A, **Akalin E**, Ames S, Bromberg JS, DeBoccardo G, DiPaola N, Lerner SM, Mehrotra A, Murphy TM, Nadasdy T, Artal EP, Salomon DR, Schröppel B, Sehgal V, Sachidanandam R, and Heeger PS. Antibody Repertoires Reactive to Non-HLA Antigens in Kidney Transplant Recipients with Transplant Glomerulopathy. *J Am Soc of Nephrol* 2011; 6: 1168-1178. doi: 10.1681/ASN.2010111183. PMID: 21566057
 36. Marfo K, **Akalin E**, Wang C, Lu A. Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients. *Am J Health system Pharm* 2011; 68 (23): 2276-2282. doi: 10.2146/ajhp110120.PMID: 22095818
 37. Marfo K, Ling M, Bao Y, Calder B, Ye B, Greenstein S, Chapochnick-Friedman J, Glicklich D, de Boccardo G, Kinkhabwala M, and **Akalin E**. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly-sensitized patients at the top of the

- waiting list. *Transplantation* 2012; 9 : 345-351. doi: 10.1097/TP.0b013e3182590d2e.PMID: 22820699
38. Ling M, Masiakos P, Ibrahim A, Lindower J, Marfo K, Glicklich D, de Boccardo G, Greenstein S, Chapochnik-Friedmann J, Kinkhabwala M, and **Akalin E**. The prevalence and significance of HLA-Cw and HLA-DP antibodies in sensitized patients on the kidney transplant waiting list. *Human Immunology* 2012; 73: 879-883. doi: 10.1016/j.humimm.2012.07.320. PMID: 22841893
 39. Nair V, Sawinski D, **Akalin E**, Friedlander R, Ebcioglu Z, Sehgal V, Dinavahi R, Khaim R, Ames S, Lerner S, Murphy B, Bromberg JS, Heeger PS, Schröppel B. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. *Clin Transplant*. 2012 May;26(3): E261-8. doi: 10.1111/j.1399-0012.2012.01657. PMID: 22686949
 40. Nicole Hayde, Yi Bao, James Pullman, Bin Ye, Brent R. Calder, Monica Chung, Daniel Schwartz, Ahmed Alansari, Graciela de Boccardo, Min Ling and **Enver Akalin**. The clinical and molecular significance of C4d staining patterns in renal allografts. *Transplantation* 2013; 95(4): 580-588. doi: 10.1097/TP.0b013e318277b2e2.PMID: 23274969
 41. Nicole Hayde, Yi Bao, James Pullman, Bin Ye, R. Brent Calder, Monica Chung, Daniel Schwartz, Michelle Lubetzky, Maria Ajaimy, Graciela de Boccardo and **Enver Akalin**. The clinical and genomic significance of donor-specific antibody (DSA) positive/C4d negative and DSA negative/C4d negative transplant glomerulopathy. *Clin J Am Soc of Nephrol* 2013; 8: 2141-2148. doi: 10.2215/CJN.04240413.PMID: 24030736
 42. Vivanco M, Friedmann P, Xia Y, Klair T, Marfo K, de Boccardo G, Greenstein S, Chapochnik-Friedmann J, Kinkhabwala M, Ajaimy M, Lubetzky ML, **Akalin E**, Kayler LK. Campath induction HCV and HCV/HIV-seropositive kidney transplant recipients. *Transpl Int*. 2013; 26(10):1016-26. doi: 10.1111/tri.12167.PMID: 23947744
 43. Marfo K, Aitken S, **Akalin E**. Clinical outcomes after conversion from brand-name tacrolimus (prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study. *PT* 2013; 38 (8) : 484-488. PMID: 24222980
 44. Nicole Hayde, Pilib OBroin, Yi Bao, Graciela de Boccardo, Michelle Lubetzky, Maria Ajaimy, James Pullman, Adriana Colovai, Aaron Golden, and **Enver Akalin**. Increased rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. *Kidney International* 2014; 86(3): 600-609. doi: 10.1038/ki.2014.75. PMID: 24670411
 45. Michelle Lubetzky, Yi Bao, Pilib Ó Broin, Kwaku Marfo, Maria Ajaimy, Aws Aljanabi, Graciela de Boccardo, Aaron Golden, and **Enver Akalin**. Genomics of BK viremia in kidney transplant recipients. *Transplantation* 2014; 97: 451-456. doi: 10.1097/01.TP.0000437432.35227.3e.PMID: 24310299
 46. Kwaku Marfo, Maria Ajaimy, Adriana Colovai, Liise Kayler, Stuart Greenstein, Michelle Lubetzky, Anjali Gupta, Layla Kamal, Graciela de Boccardo, Peter Masiakos, Milan Kinkhabwala, and **Enver Akalin**. Pre-transplant immunologic risk assessment of kidney transplant recipients with donor-Specific anti-HLA antibodies. *Transplantation* 2014; 98: 1082-1088. doi: 10.1097/TP.000000000000191.PMID: 24873780
 47. Lee BT, Gabardi S, Grafals M, Hofmann RM, **Akalin E**, Aljanabi A, Mandelbrot DA, Adey DB, Heher E, Fan PY, Conte S, Dyer-Ward C, Chandraker A. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial *CJASN* 2014; 9: 583-589. doi: 10.2215/CJN.04230413. PMID: 24482066

48. Pilib Ó Broin, Nicole Hayde, Yi Bao, Bin Ye, Brent Calder, Graciela de Boccardo, Michelle Lubetzky, Maria Ajaimy, James Pullman, Adriana Colovai, **Enver Akalin** and Aaron Golden. A pathogenesis-based transcript signature in donor-specific antibody-positive kidney transplant recipients with normal biopsies. *Genom Data* 2014; 2: 357-360. doi: 10.1016/j.gdata.2014.10.005.PMID: 26484130
49. Michelle Lubetzky, Maria Ajaimy, Layla Kamal, Graciela de Boccardo, **Enver Akalin**, and Liise Kayler. Kidney transplant complications from undiagnosed benign prostatic hypertrophy. *Clinical Transplantation* 2015; 29(6): 539-542. doi: 10.1111/ctr.12548. PMID: 25832848
50. Layla Kamal, Pilib Ó Broin, Yi Bao, Maria Ajaimy, Michelle Lubetzky, Anjali Gupta, Graciela de Boccardo, James Pullman, Aaron Golden, and **Enver Akalin**. Clinical, histological, and molecular markers associated with allograft loss in transplant glomerulopathy patients. *Transplantation* 2015, 99(9); 1912-1918. doi: 10.1097/TP.0000000000000598.PMID: 25675205
51. Ajaimy M, Lubetzky M, Kamal L, Gupta A, Dunn C, de Boccardo G, **Akalin E**, and Kayler L. Kidney transplantation in patients with severe preoperative hypertension. *Clinical Transplantation* 2015; 29(9): 781-785. doi: 10.1111/ctr.12579. PMID: 26084790
52. Anjali Gupta, Pilib Ó Broin, Yi Bao, James Pullman, Layla Kamal, Maria Ajaimy, Michelle Lubetzky, Adriana Colovai, Daniel Schwartz, Graciela de Boccardo, Aaron Golden and **Enver Akalin**. Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. *Kidney International* 2016; 89: 217-225. doi: 10.1038/ki.2015.276. PMID: 26422506
53. Sumeyye Calp-Inal, Maria Ajaimy, Michal L. Melamed, Christina Savchik, Peter Masiakos, Adriana Colovai and **Enver Akalin**. The prevalence and clinical significance of C1q binding donor-specific anti-HLA antibodies early and late after kidney transplantation. *Kidney International* 2016; 89: 209-216. doi: 10.1038/ki.2015.275. PMID: 26535999
54. Ajaimy M, Lubetzky M, Jones T, Kamal L, Colovai A, de Boccardo G, **Akalin E**. Pregnancy in sensitized kidney transplant recipients: a single center experience. *Clinical Transplantation* 2016; 30(7): 791-795. doi: 10.1111/ctr.12751.PMID: 27101447
55. Michelle Lubetzky, Soohwan Chun, Andrew Joelson, Maria Coco, Layla Kamal, Maria Ajaimy, Paul Gaglio, **Enver Akalin** and Graciela Deboccardo. Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients with Directly Acting Antiviral Agents. *Transplantation* 2017; 101: 1704-1710. doi: 10.1097/TP.0000000000001618. PMID: 28009781
56. A Loupy, M Haas, K Solez, L Racusen, D Glotz, D Seron, B Nankivell, R B Colvin, M. Afrouzian, **E. Akalin**, N. Alachkar, S. Bagnasco, J. Becker, L. Cornell, C Drachenberg, D Dragun, I. Gibson, E S Kraus, C. Lefaucheur, H. Liapis, T Muthukumar, V. Nickleit, B. Orandi, M Rabant, P. Randhawa, E Reed C. Roufosse, S. Sehan, B. Sis, S. Singh, C. Schinstock, A Tambur, A Zeevi, M. Mengel. The Banff 2015 Kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. *Am J Transpl* 2017; 17: 28-41. doi: 10.1111/ajt.14107.PMID: 27862883

57. Colovai AI, Ajaimy M, Kamal LG, Masiakos P, Chan S, Savchik C, Lubetzky M, de Boccardo G, Courson A, Chokechanachaisakul A, Graham J, Greenstein S, Kinkhabwala M, Rocca J, **Akalin E**. Increased Access to Transplantation of Highly Sensitized Patients Under the New Kidney Allocation System. A Single Center Experience. *Human Immunol* 2017; 78: 257-262. doi: 10.1016/j.humimm.2016.12.003. PMID: 27955974
58. Philip F. Halloran, **Enver Akalin**, Olivier Aubert, Georg Bohmig, Daniel Brennan, Jonathan Bromberg, Gunilla Einecke, Farsad Eskandary, Clement Gosset, Gaurav Gupta, Carmen Lefaucheur, Andrew Malone, Daniel Seron, Joana Sellares, Matt Weir, and Alexandre Loupy. Real time central assessment of kidney transplant indication biopsies by microarrays: The INTERCOMEX Study. *Am J Transplant*. 2017 Nov;17(11):2851-2862. doi: 10.1111/ajt.14329. PMID: 28449409
59. Bontha SV, Maluf DG, Archer KJ, Dumur CI, Dozmorov MG, King AL, **Akalin E**, Mueller TF, Gallon L, Mas VR. Efficacy DNA methylation on progression to interstitial fibrosis and tubular atrophy in renal allograft biopsies. A multi-omics approach. *Am J Transplant*. 2017 Dec;17(12):3060-3075. doi: 10.1111/ajt.14372. PMID: 28556588
60. Torabi J, Rocca JP, Choinski K, Lorenzen K, Yongue C, Lubetzky ML, Herbert ME, Chokechanachaisakul A, Ajaimy M, Kamal L, **Akalin E**, Kinkhabwala M, Graham JA. Improving pancreas graft utilization through importation. *Clin Transplant*. 2018 Jan;32(1). doi: 10.1111/ctr.13154. PMID: 29140549
61. M Haas, A Loupy, C Lefaucheur, C Roufousse, D Glotz, D Seron, B J Nankivell, P F Halloran, R B Colvin, **E. Akalin**, N Alachkar, S Bagnasco, Y Bouatou, J U Becker, L Cornell, JP Duong van Huyen, I Gibson, R Mannon, M, Naesens, V Nickleit, P Nickerson, D L Segev, H K Singh, M Stegall, P Randhawa, L Racusen, K Solez, M Mengel. The Banff 2017 Kidney Meeting Report: Revised Diagnostic Criteria for Chronic Active T Cell-Mediated Rejection, Antibody-Mediated Rejection, and Prospects for Integrative Endpoints for Next-Generation Clinical Trials. *Am J Transplant*. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. PMID: 29243394
62. Lubetzky M, Kamal L, Ajaimy M, **Akalin E**, Kayler L. Hospital readmissions in diabetic kidney transplant recipients with peripheral vascular disease. *Clin Transplant* 2018 Apr 28; e13271. doi: 10.1111/ctr.13271. PMID: 29704405
63. Uffing A, Pérez-Sáez MJ, La Manna G, Comai G, Fischman C, Farouk S, Manfro RC, Bauer AC, Lichtenfels B, Mansur JB, Tedesco-Silva H, Kirsztajn GM, Manonelles A, Bestard O, Riella MC, Hokazono SR, Arias-Cabrales C, David-Neto E, Ventura CG, **Akalin E**, Mohammed O, Khankin EV, Safa K, Malvezzi P, O'Shaughnessy MM, Cheng XS, Cravedi P, Riella LV. A large international study on posttransplant glomerular diseases: the Tango Project. *BMC Nephrol*. 2018 Sep 12;19(1):229. doi: 10.1186/s12882-018-1025-z. PMID: 3020888
64. Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. *J Am Soc Nephrol*. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. PMID: 29752413
65. Hall IE, **Akalin E**, Bromberg JS, Doshi MD, Greene T, Harhay MN, Jia Y, Mansour SG, Mohan S, Muthukumar T, Reese PP, Schröppel B, Singh P, Thiessen-Philbrook HR, Weng FL, Parikh CR. Deceased-donor acute kidney injury is not associated with kidney allograft

- failure. *Kidney Int.* 2019 Jan;95(1):199-209. doi: 10.1016/j.kint.2018.08.047. PMID: 30470437
66. Lubetzky M, Hayde N, Ó Broin P, Ajaimy M, Bao Y, Mohammed O, Schwartz D, Pullman J, **Akalin E**. Molecular Signatures and Clinical Outcomes of Transplant Glomerulopathy Stratified by Microvascular Inflammation and Donor-Specific Antibody. *Clin Transplant.* 2018 Dec 22; e13469. doi: 10.1111/ctr.13469. PMID: 30578675
 67. Uffing A, Hidalgo LG, McMullan C, Perry J, Milford EL, Murakami N, Yeung MY, Guleria I, Wood IG, **Akalin E**, Azzi J, Chandraker AK, Riella LV. Preformed donor-specific antibodies against class II and graft outcomes in deceased-donor kidney transplantation. *Transplant Direct.* 2019 Apr 15;5(5): e446. doi: 10.1097/TXD.0000000000000893. PMID: 31165081
 68. Torabi J, Graham JA, Choiniski K, Suresh S, Chokechanachaisakul A, Ajaimy M, Kamal L, **Akalin E**, Kinkhabwala M, Greenstein S, Rocca JP. Young donors with severe acute kidney injury offers an opportunity to expand the donor pool. *Am J Surg.* 2019, Jul;218(1):7-13. doi: 10.1016/j.amjsurg.2019.04.005. PMID: 31003717
 69. Koyawala N, Reese PP, Hall IE, Jia Y, Thiessen-Philbrook HR, Mansour SG, Doshi MD, **Akalin E**, Bromberg JS, Harhay MN, Mohan S, Muthukumar T, Schröppel B, Singh P, Weng FL, Parikh CR. Urine injury biomarkers are not associated with kidney transplant failure. *Transplantation.* 2020 Jun;104(6):1272-1279. doi: 10.1097/TP.0000000000002948. PMID: 31568213
 70. Graham JA, Ajaimy M, Carrero J, Jones T, Torabi J, Alani O, **Akalin E**, Rocca JP. Hepatitis C Virus Positivity Should Not Be Included in the Kidney Donor Profile Index Calculation When Transplanting HCV-Positive Kidneys Into Non-infected Recipients in the Era of Direct-Acting Antiviral Agents. *Prog Transplant.* 2019 Dec;29(4):371-372. doi: 10.1177/1526924819874373. PMID: 31533529
 71. Schröppel B, **Akalin E**, Baweja M, Bloom RD, Florman S, Goldstein M, Haydel B, Hricik DE, Kulkarni S, Levine M, Mehrotra A, Patel A, Poggio ED, Ratner L, Shapiro R, Heeger PS. Peri-transplant eculizumab does not prevent delayed kidney function in deceased donor kidney transplant recipients: results of two randomized controlled pilot trials. *Am J Transplant.* 2020 Feb;20(2):564-572. doi: 10.1111/ajt.15580. PMID: 31452319
 72. **Akalin E**, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, Ross M, Forest S, Goldstein YD, Ajaimy M, Liriano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M. COVID-19 and kidney transplantation. *N Engl J Med.* 2020 Jun 18;382(25):2475-2477. doi: 10.1056/NEJMc2011117. PMID: 32329975
 73. Kaminski MM, Alcantar MA, Lape IT, Greensmith R, Huske AC, Valeri JA, Marty FM, Klämbt V, Azzi J, **Akalin E**, Riella LV, Collins JJ. A CRISPR-based Assay for the Detection of Opportunistic Infections Post-Transplantation and for the Monitoring of Transplant Rejection. *Nat Biomed Eng.* 2020 Jun;4(6):601-609. doi: 10.1038/s41551-020-0546-5. PMID: 32284553
 74. Torabi J, Rocca JP, Kestenbaum E, Ajaimy M, DeFeo M, Konicki A, Liriano- Ward L, Azzi Y, Pynadath C, **Akalin E**, Kinkhabwala M, Graham JA. Preoperative C-peptide predicts weight gain after pancreas transplantation. *Prog Transplant.* 2020 Jun;30(2):117-124. doi: 10.1177/1526924820913518. PMID: 32242484
 75. Torabi J, Konicki A, Rocca JP, Ajaimy M, Campbell A, Azzi Y, Pynadath C, Liriano-Ward L, **Akalin E**, Kinkhabwala M, Graham JA. The use of LCP-Tacrolimus (Envarsus XR) in simultaneous pancreas and kidney (SPK) transplant recipients. *Am J Surg.* 2020 Apr;219(4):583-586. doi: 10.1016/j.amjsurg.2020.02.027. PMID: 32122660

76. Uffing A, Pérez-Sáez MJ, Mazzali M, Manfro RC, Bauer AC, de Sottomaio Drumond F, O'Shaughnessy MM, Cheng XS, Chin KK, Ventura CG, Agena F, David-Neto E, Mansur JB, Kirsztajn GM, Tedesco-Silva H Jr, Neto GMV, Arias-Cabrales C, Buxeda A, Bugnazet M, Jouve T, Malvezzi P, **Akalin E**, Alani O, Agrawal N, La Manna G, Comai G, Bini C, Muhsin SA, Riella MC, Hokazono SR, Farouk SS, Haverly M, Mothi SS, Berger SP, Cravedi P, Riella LV. Recurrence of FSGS after Kidney Transplantation in Adults. *Clin J Am Soc Nephrol*. 2020 Feb 7;15(2):247-256. doi: 10.2215/CJN.08970719. PMID: 31974287
77. Graham JA, Torabi J, Ajaimy M, **Akalin E**, Liriano LE, Azzi Y, Pynadath C, Greenstein SM, Goldstein FY, Fox AS, Weiss JM, Powell TP, Reinus JF, Kinkhabwala MM, Rocca JP. Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access. *Clin Transplant*. 2020 Apr;34(4):e13833. doi: 10.1111/ctr.13833. PMID: 32072689
78. Aleksic S, Eisenberg R, Tsomos E, Zahedpour Anaraki S, Japp E, Upadhyay L, Mowrey WB, **Akalin E**, Zonszein J. Glycemic management and clinical outcomes in underserved minority kidney transplant recipients with type 2 and posttransplantation diabetes: A single-center retrospective study. *Diabetes Res Clin Pract*. 2020 Jul; 165:108221. doi: 10.1016/j.diabres.2020.108221. PMID: 32442553
79. Mengel M, Loupy A, Haas M, Roufosse C, Naesens M, **Akalin E**, Clahsen-van Groningen MC, J Dagobert, Demetris AJ, Duong van Huyen JP, Gueguen J, Issa F, Robin B, Rosales I, Von der Thüsen JH, Sanchez-Fueyo A, Smith RN, Wood K, Adam B, Colvin RB. Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation - Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. *Am J Transplant*. 2020 Sep;20(9):2305-2317. doi: 10.1111/ajt.16059. PMID: 32428337
80. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, **Akalin E**, Alachkar N, Bagnasco S, Becker JU, Cornell LD, Clahsen-van Groningen MC, Demetris AJ, Dragun D, Duong van Huyen JP, Farris AB, Fogo AB, Gibson IW, Glotz D, Gueguen J, Kikic Z, Kozakowski N, Kraus E, Lefaucheur C, Liapis H, Mannon RB, Montgomery RA, Nankivell BJ, Nickleit V, Nickerson P, Rabant M, Racusen L, Randhawa P, Robin B, Rosales IA, Sapir-Pichhadze R, Schinstock CA, Seron D, Singh HK, Smith RN, Stegall MD, Zeevi A, Solez K, Colvin RB, Mengel M. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. *Am J Transplant*. 2020 Sep;20(9):2318-2331. doi: 10.1111/ajt.15898. PMID: 32463180
81. Azzi Y, Parides M, Alani O, Loarte-Campos P, Bartash R, Forest S, Colovai A, Ajaimy M,

- Liriano- Ward L, Pynadath C, Graham J, Le M, Greenstein S, Rocca J, Kinkhabwal M, **Akalin E**. COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. *Kidney Int*. 2020 Dec;98(6):1559-1567. PMID:33069762
82. C Wiseman A, **Akalin E**, Dadhania D, DeMattos A, Doshi M, Friedewald J, Klein C, Leca N, Nicoll K, Pesavento T, Preczewski L, Samaniego M, Singh N, Bloom R. Defining the roles and responsibilities of the kidney transplant medical director: A necessary step for future training mentoring and professional development. *Am J Transplant*. 2021 Apr;21(4):1556-1563. doi: 10.1111/ajt.16332. PMID: 33021008
 83. Torabi J, Melvin J, Rechnitzer A, Rocca JP, Ajaimy M, Lirano-Ward L, Azzi Y, Pynadath C, Alani O, **Akalin E**, Graham JA. High terminal creatinine donors should not preclude simultaneous kidney and pancreas transplantation. *Am J Surg*. 2021 Apr;221(4):677-680. doi: 10.1016/j.amjsurg.2020.09.031. PMID: 33012501
 84. Torabi J, Rocca JP, Ajaimy M, Melvin J, Campbell A, **Akalin E**, Liriano LE, Azzi Y, Pynadath C, Greenstein SM, Le M, Goldstein DY, Fox AS, Carrero J, Weiss JM, Powell T, Racine AD, Reinus JF, Kinkhabwala MM, Graham JA. Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients. *Transpl Infect Dis*. 2021 Feb;23(1):e13449. doi: 10.1111/tid.13449. PMID: 32810315
 85. Raynaud M, Aubert O, Reese PP, Bouatou Y, Naesens M, Kamar N, Bailly É, Giral M, Ladrière M, Le Quintrec M, Delahousse M, Juric I, Basic-Jukic N, Gupta G, **Akalin E**, Yoo D, Chin CS, Proust-Lima C, Böhmig G, Oberbauer R, Stegall MD, Bentall AJ, Jordan SC, Huang E, Glotz D, Legendre C, Montgomery RA, Segev DL, Empana JP, Grams ME, Coresh J, Jouven X, Lefaucheur C, Loupy A. Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. *Kidney Int*. 2021 Jan;99(1):186-197.
 86. Mansour SG, Liu C, Jia Y, Reese PP, Hall IE, El-Achkar TM, LaFavers KA, Obeid W, Rosenberg AZ, Daneshpajouhnejad P, Doshi MD, **Akalin E**, Bromberg JS, Harhay MN, Mohan S, Muthukumar T, Schröppel B, Singh P, El-Khoury JM, Weng FL, Thiessen-Philbrook HR, Parikh CR. Uromodulin to Osteopontin Ratio in Deceased Donor Urine is Associated with Kidney Graft Outcomes. *Transplantation* 2021 Apr 1;105(4):876-885. doi: 10.1097/TP.0000000000003299. PMID: 32769629
 87. Cravedi P, Mothi SS, Azzi Y, Haverly M, Farouk SS, Pérez-Sáez MJ, Redondo-Pachón MD, Murphy B, Florman S, Cyrino LG, Grafals M, Venkataraman S, Cheng XS, Wang AX, Zaza G, Ranghino A, Furian L, Manrique J, Maggiore U, Gandolfini I, Agrawal N, Patel H, **Akalin E**, Riella LV. COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. *Am J Transplant*. 2020 Nov;20(11):3140-3148. doi: 10.1111/ajt.16185. Epub 2020 Aug 4. PMID: 32649791
 88. Kobashigawa J, Dadhania DM, Farr M, Tang WHW, Bhimaraj A, Czer L, Hall S, Haririan A, Formica RN, Patel J, Skorka R, Fedson S, Srinivas T, Testani J, Yabu JM, Cheng XS; Consensus Conference Participants. Consensus conference on heart and kidney transplantation. *Am J Transplant*. 2021 Jul;21(7):2459-2467. doi: 10.1111/ajt.16512. PMID: 33527725
 89. Uffing A, Pérez-Saéz MJ, Jouve T, Bugnazet M, Malvezzi P, Muhsin SA, Lafargue MC, Reindl-Schwaighofer R, Morlock A, Oberbauer R, Buxeda A, Burballa C, Pascual J, von Moos S, Seeger H, La Manna G, Comai G, Bini C, Russo LS, Farouk S, Nissaisorakarn P, Patel H, Agrawal N, Mastroianni-Kirsztajn G, Mansur J, Tedesco-Silva H, Ventura CG, Agena F, David-Neto E, **Akalin E**, Alani O, Mazzali M, Manfro RC, Bauer AC, Wang AX, Cheng XS, Schold JD, Berger SP, Cravedi P, Riella LV. Recurrence of IgA nephropathy after

- kidney transplantation in adults. *Clin J Am Soc Nephrol*. 2021 Aug;16(8):1247-1255. doi: 10.2215/CJN.00910121.PMID: 34362788
90. Kuscu C, Kiran M, Mohammed A, Kuscu C, Satpathy S, Wolen A, Bardhi E, Bajwa A, Eason JD, Maluf D, Mas V, **Akalin E**. Integrative analysis of circulating small RNAs and kidney graft transcriptome in transplant glomerulopathy. *Int J Mol Sci*. 2021 Jun 9;22(12):6218. doi: 10.3390/ijms22126218.PMID: 34207555
 91. Hall IE, Reese PP, Mansour SG, Mohan S, Jia Y, Thiessen-Philbrook HR, Brennan DC, Doshi MD, Muthukumar T, **Akalin E**, Harhay MN, Schröppel B, Singh P, Weng FL, Bromberg JS, Parikh CR. Deceased donor kidney injury BK polyomavirus in kidney transplant recipients. *Clin J Am Soc Nephrol*. 2021 May 8;16(5):765-775. doi: 10.2215/CJN.18101120. PMID: 33692117
 92. Azzi Y, Nair G, Loarte-Campos P, Ajaimy M, Graham J, Liriano-Ward L, Pynadath C, Uehlinger J, Parides M, Campbell A, Colovai A, Alani O, Le M, Greenstein S, Kinkhabwala M, Rocca J, **Akalin E**. A safe anti-A2 titer for a successful A2 incompatible kidney transplantation: A single-center experience and review of the literature. *Transplant Direct*. 2021 Jan 26;7(2):e662. doi: 10.1097/TXD.0000000000001099. PMID: 33521251
 93. Alasfar S, Hall IE, Mansour SG, Jia Y, Thiessen-Philbrook HR, Weng FL, Singh P, Schröppel B, Muthukumar T, Mohan S, Malik RF, Harhay MN, Doshi MD, **Akalin E**, Bromberg JS, Brennan DC, Reese PP, Parikh CR. Contemporary incidence and risk factors of posttransplant erythrocytosis in deceased donor kidney transplantation. *BMC Nephrol*. 2021 Jan 12;22(1):26. doi: 10.1186/s12882-021-02231-2.PMID: 33435916
 94. Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, Pang APS, Sugai C, Mahyari E, Francisco EB, Pise A, Rodrigues H, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Bimber BN, Plassmeyer M, Gupta R, Alpan O, O'Halloran JA, Mudd PA, **Akalin E**, Ndhlovu LC, Sacha JB. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. *Int J Infect Dis*. 2021 Feb; 103:25-32. doi: 10.1016/j.ijid.2020.10.101. PMID: 33186704
 95. Cravedi P, Ahearn P, Wang L, Yalamarti T, Hartzell S, Azzi Y, Menon M, Jain A, Billah M, Fernandez-Vina M, Gebel H, Woodle E, Haddad N, Morrison-Porter A, Lee FE, Sanz I, **Akalin E**, Girnita A, Maltzman J. Delayed kinetics of IgG, but not IgA, anti-spike antibodies in transplant recipients after SARS-CoV-2 infection. *J Am Soc Nephrol*. 2021 Oct 1;32(12):3221-30. doi: 10.1681/ASN.2021040573. PMID: 34599041
 96. Raynaud M, Aubert O, Divard G, Reese PP, Kamar N, Yoo D, Chin CS, Bailly É, Buchler M, Ladrière M, Le Quintrec M, Delahousse M, Juric I, Basic-Jukic N, Crespo M, Silva HT Jr, Linhares K, Ribeiro de Castro MC, Soler Pujol G, Empana JP, Ulloa C, **Akalin E**, Böhmig G, Huang E, Stegall MD, Bentall AJ, Montgomery RA, Jordan SC, Oberbauer R, Segev DL, Friedewald JJ, Jouven X, Legendre C, Lefaucheur C, Loupy A. Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. *Lancet Digit Health*. 2021 Dec;3(12):e795-e805. doi: 10.1016/S2589-7500(21)00209-0. PMID: 34756569
 97. Madill-Thomsen KS, Böhmig GA, Bromberg J, Einecke G, Eskandary F, Gupta G, Hidalgo LG, Myslak M, Viklicky O, Perkowska-Ptasinska A, Halloran PF; INTERCOMEX Investigators. Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection. *J Am Soc Nephrol*. 2021 Nov;32(11):2743-2758. doi: 10.1681/ASN.2021040433. PMID: 34253587

98. Archer KJ, Bardhi E, Maluf DG, McDaniels J, Rousselle T, King A, Eason JD, Gallon L, **Akalin E**, Mueller TF, Mas VR. Pretransplant kidney transcriptome captures intrinsic donor organ quality and predicts 24-month outcomes. *Am J Transplant*. 2022 Jun 22. doi: 10.1111/ajt.17127. PMID: 35730259
99. **Akalin E**, Weir MR, Bunnapradist S, Brennan DC, Delos Santos R, Langone A, Djamali A, Xu H, Jin X, Dholakia S, Woodward RN, Bromberg JS. Clinical validation of an immune quiescence gene expression signature in kidney transplantation. *Kidney360*. 2021 Sep 28;2(12):1998-2009. doi: 10.34067/KID.0005062021.PMID: 35419538
100. Malik RF, Jia Y, Mansour SG, Reese PP, Hall IE, Alasfar S, Doshi MD, **Akalin E**, Bromberg JS, Harhay MN, Mohan S, Muthukumar T, Schröppel B, Singh P, Weng FL, Thiessen Philbrook HR, Parikh CR. Posttransplant diabetes mellitus in kidney transplant recipients: A multicenter study. *Kidney360*. 2021 Jun 2;2(8):1296-1307. doi: 10.34067/KID.0000862021. PMID: 35369651
101. Mansour SG, Khoury N, Kodali R, Virmani S, Reese PP, Hall IE, Jia Y, Yamamoto Y, Thiessen-Philbrook HR, Obeid W, Doshi MD, **Akalin E**, Bromberg JS, Harhay MN, Mohan S, Muthukumar T, Singh P, Weng FL, Moledina DG, Greenberg JH, Wilson FP, Parikh CR. Clinically adjudicated deceased donor acute kidney injury and graft outcomes. *PLoS One*. 2022 Mar 3;17(3): e0264329. doi: 10.1371. PMID: 35239694
102. Sun Z, Zhang Z, Banu K, Azzi YA, Reghuvaran A, Fredericks S, Planoutene M, Hartzell S, Pell J, Tietjen G, Asch W, Kulkarni S, Formica R, Rana M, Zhang W, **Akalin E**, Cravedi P, Heeger PS, Menon MC. Blood transcriptomes of SARS-CoV2 infected kidney transplant recipients demonstrate immune deficiency. *medRxiv*. 2022 Feb 1:2022.01.31.22270203. doi: 10.1101. PMID: 35132424
103. Singh N, Doshi MD, Schold JD, Preczewski L, Klein C, **Akalin E**, Leca N, Nicoll K, Pesavento T, Dadhania DM, Friedewald J, Samaniego-Picota M, Bloom RD, Wiseman AC. Survey of salary and job satisfaction of transplant nephrologists in the United States. *Clin J Am Soc Nephrol*. 2022 Aug 1: CJN.03490322. doi: 10.2215. PMID: 35914792
104. Reese PP, Doshi MD, Hall IE, Besharatian B, Bromberg JS, Thiessen-Philbrook H, Jia Y, Kamoun M, Mansour SG, **Akalin E**, Harhay MN, Mohan S, Muthukumar T, Schröppel B, Singh P, Weng FL, Parikh CR. Deceased-donor acute kidney injury and acute rejection in kidney transplant recipients: A multicenter cohort. *Am J Kidney Dis*. 2022 Sep 30:S0272-6386(22)00920-9. PMID: 36191727
105. Girnita AL, Wang L, Colovai AI, Ahearn P, Azzi Y, Menon MC, Fernandez-Vina M, Gebel HM, Steve Woodle E, Cravedi P, Maltzman JS, **Akalin E**. Analysis of cross-sectional and longitudinal HLA and anti-viral responses after COVID infection in COVID in renal allograft recipients: Differences and correlates. *Transplantation*. 2022 Oct 1;106(10):2085-2091. PMID: 36070571
106. Chancay J, Liu C, Chauhan K, Andersen L, Harris C, Coca S, Delaney V, Tedla F, De Boccardo G, Sehgal V, Moledina D, Formica R, Reghuvaran A, Banu K, Florman S, **Akalin E**, Shapiro R, Salem F, Menon MC. Role of time from transplantation to biopsy histologic ABMR: A single center report. *Clin Transplant*. 2022 Sep 7:e14802. doi: 10.1111/ctr.14802. PMID: 36069577
107. Madill-Thomsen KS, Böhmig GA, Bromberg J, Einecke G, Eskandary F, Gupta G, Myslak M, Viklicky O, Perkowska-Ptasinska A, Solez K, Halloran PF; INTERCOMEX Investigators. Relating molecular T cell mediated rejection activity in kidney transplant biopsies to time and to histological tubulitis and atrophy/fibrosis. *Transplantation*. 2022 Dec

28. doi: 10.1097/TP.0000000000004396.
108. Truchot A, Raynaud M, Kamar N, Naesens M, Legendre C, Delahousse M, Thaunat O, Buchler M, Crespo M, Linhares K, Orandi BJ, **Akalin E**, Pujol GS, Silva HT Jr, Gupta G, Segev DL, Jouven X, Bentall AJ, Stegall MD, Lefaucheur C, Aubert O, Loupy A. Machine learning does not outperform traditional statistical modelling for kidney allograft failure prediction. *Kidney Int.* 2022 Dec 23;S0085-2538(22)01084-5. doi: 10.1016/j.kint.2022.12.011. PMID: 36572246
109. Sun Z, Zhang Z, Banu K, Azzi YA, Reghuvaran A, Fredericks S, Planoutene M, Hartzell S, Kim Y, Pell J, Tietjen G, Asch W, Kulkarni S, Formica R, Rana M, Maltzman JS, Zhang W, **Akalin E**, Heeger PS, Cravedi P, Menon MC. Blood transcriptomics of SARS-CoV-2 infected kidney transplant recipients associated with immune deficiency proportionate to severity. *J Am Soc Nephrol.* 2022 Nov;33(11):2108-2122. doi: 10.1681/ASN.2022010125. PMID: 36041788
110. Lee J, Barbachan E Silva M, Bao Y, Whitmarsh R, Banerjee S, O'Connor J, Holbert J, Bratton TK, Broin PÓ, **Akalin E**. Performance and advancement of the Kidney Solid Organ Response Test. *Transplantation.* 2023, 107(10): 2271-2278. PMID: 37322587

LETTERS AND CASE REPORTS

1. Akcicek F, Dilber S, Ozgen G, Ok E, **Akalin E**, Basci A, Guclu A, Dorhout Mees EJ. Spontaneous perirenal hematoma due to periarteritis nodosa. *Nephron* 1994; 68: 396. doi: 10.1159/000188413.PMID: 7838273
2. **Akalin E**, Hyde C, Schmitt G, Kaufman J, Hamburger RJ. Emphsematous cystitis and pyelitis in a diabetic renal transplant recipient. *Transplantation* 1996; 62: 1024-1026. doi: 10.1097/00007890-199610150-00023.PMID: 8878399
3. Ustundag Y, Hizel N, Boyacioglu S, **Akalin E**. Detection of hepatitis GB virus-C and HCV genomes in the saliva of patients undergoing maintenance haemodialysis(letter). *Nephrology, Dialysis, Transplantation* 1997, 12(12) :2807. doi: 10.1093/ndt/12.12.2807a.PMID: 9430914
4. **Akalin E**, Chandrakantan A, Keane J, Hamburger RJ. Normouricemia in the syndrome of inappropriate antidiuretic hormone secretion. *Am J Kid Dis* 2001; 37 :E8. doi: 10.1016/s0272-6386(01)90005-8. PMID: 11136197
5. **Akalin E**, Bromberg JS, Sehgal V, Ames S, Daly L, Murphy B. Decreased incidence of cytomegalovirus infection in thymoglobulin treated kidney transplant patients with 6 months valganciclovir prophylaxis. *Am J Transplant* 2003; 4:148-149. doi: 10.1046/j.1600-6143.2003.00308. PMID: 14678049
6. **Akalin E**, Sehgal V, Ames S, Dikman S, Fotino M, Bromberg JS, Murphy B. Intravenous immunoglobulin treatment in a kidney transplant patient with chronic allograft nephropathy. *Transplantation* 2005; 79: 257-258. doi: 10.1097/01.tp.0000144331.18842.34.PMID: 15665787
7. **Akalin E**, Ames S, Sehgal V, Murphy B, Fotino M, Friedlander R, Bromberg JS. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk living kidney transplant recipients. *Transplantation* 2005; 79: 742
8. Herman ES, Rafey MA, **Akalin E**, Winston JA, Murphy B. Blood pressure and renal function after kidney donation from hypertensive living donors. Letter to the editor. *Transplantation* 2005;79: 1768-1769

9. Wyatt C, Dikman S, Sehgal V, Murphy B, Ames S, Bromberg JS, **Akalin E**. Chronic organizing microangiopathy in a kidney transplant recipient. *Nephrology, Dialysis, and Transplantation* 2005; 20:1734-1737. doi: 10.1093/ndt/gfh929. PMID: 15956067
10. Marfo K, Chapochnick-Friedmann J, **Akalin E**, Lu A. Postexposure prophylaxis of H1N1 with oseltamivir in a newly transplanted kidney recipient receiving intense immunosuppressive therapy. *Transplant Proceedings* 2009; 41(10), 4411-3. doi: 10.1016/j.transproceed.2009.09.052. PMID: 20005410
11. Marfo K and **Akalin E**. Reply to “Defining the benefits of desensitization”. *Transplantation* 2013; 95(6): 33-34. doi: 10.1097/TP.0b013e3182846013. PMID: 23507653
12. Azzi Y, Raees H, Wang T, Cleare L, Liriano-Ward L, Loarte-Campos P, Pynadath C, Ajaimy M, Alani O, Bao Y, Pirofski LA, **Akalin E**. Risk factors associated with poor response to COVID-19 vaccination in kidney transplant recipients. *Kidney Int.* 2021 Nov;100(5):1127-1128. doi: 10.1016/j.kint.2021.08.019. PMID: 34481804